Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ICOS Corporation -- Ignore unavailable to you. Want to Upgrade?

To: SemiBull who wrote (994)	6/25/2003 8:05:00 PM
From: SemiBull	Read Replies (1) \| Respond to of 1139

Studies Find Lilly's Impotence Drug Safe Wednesday June 25, 2:09 pm ET NEW YORK (Reuters) - Drugmakers Eli Lilly and Co. (NYSE:LLY - News) and Icos Corp. (NasdaqNM:ICOS - News) said on Wednesday clinical trials of their new anti-impotence drug showed it to be safe, with only minor side effects. The drug, Cialis, which is already sold in Europe but is awaiting approval in the United States and Canada, is expected to compete with Pfizer Inc's (NYSE:PFE - News) Viagra. The new data, presented at the Canadian Urological Association meeting in Toronto, found the most common adverse side affects to be headache and upset stomach. The U.S. Food and Drug Administration (News - Websites) in April 2002 had given conditional approval of the drug, but said final approval was dependent on further data. The two companies have never said what the FDA was seeking, but analysts have speculated that it was a safety issue due to the length of time the drug remains in the system. The 18-month study of 1,100 men with erectile dysfunction showed the side effects occurred in about 10 percent to 15 percent of patients. Of those, 6 percent stopped taking the drug due to side effects. The companies said any single side effect, such as headaches, accounted for less than 1 percent of discontinuations. A second study of safety and tolerability in patients who were also taking medication for high blood pressure showed no increase in adverse side effects, the companies said. Icos shares were up $1.57, or 4.3 percent at $38.32 in trade on Nasdaq. Eli Lilly shares were off 7 cents to $68.59 on the New York Stock Exchange (News - Websites).